Cancer Family
Peritoneal Neoplasm
CI-CAN-00000318Explore in graph →
Non-malignant142 active trials5 approved drugs2 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000318Explore in graph →
Clinical trials
592 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06714617 | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 3 | SystImmune Inc.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05194072 | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | terminated | Phase 1 | 250 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 5 | Jan 9, 2026 | clinicaltrials |
| NCT05200364 |
| A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer |
| terminated |
| Phase 1 |
| 58 |
| Sutro Biopharma, Inc.INDUSTRY |
| 1 |
| Sep 22, 2025 |
| clinicaltrials |
| NCT05708924 | MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | terminated | Phase 1 | 1 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT04611126 | T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer | terminated | Phase 1 / Phase 2 | 6 | Inge Marie SvaneOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05274451 | A Study to Investigate LYL797 in Adults With Solid Tumors | terminated | Phase 1 | 57 | Lyell Immunopharma, Inc.INDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT04019288 | AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | terminated | Phase 1 | 221 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT03585764 | MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 1 | 46 | University of PennsylvaniaOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT05261490 | Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 10 | PfizerINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03691376 | Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 1 | 4 | Roswell Park Cancer InstituteOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05001282 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) | terminated | Phase 1 / Phase 2 | 79 | Elucida OncologyINDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT05538624 | A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary | terminated | Phase 1 / Phase 2 | 14 | Avenge Bio, IncINDUSTRY | 1 | Apr 24, 2024 | clinicaltrials |
| NCT05581719 | A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy | terminated | Phase 1 / Phase 2 | 14 | Enlivex Therapeutics RDO Ltd.INDUSTRY | 2 | Apr 17, 2024 | clinicaltrials |
| NCT04814875 | A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy | terminated | Phase 1 / Phase 2 | 16 | THERAPIM PTY LTDINDUSTRY | 1 | Feb 14, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT01099644 | Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum | terminated | Phase 1 | 54 | Y-mAbs TherapeuticsINDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT03924245 | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers | terminated | Phase 1 | 3 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT03608618 | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma | terminated | Phase 1 | 14 | MaxCyte, Inc.INDUSTRY | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02485990 | Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) | terminated | Phase 1 | 24 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 12, 2021 | clinicaltrials |
| NCT01952249 | A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian(SIERRA) | terminated | Phase 1 | 20 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 9, 2020 | clinicaltrials |
| NCT01535157 | Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer | terminated | Phase 1 / Phase 2 | 12 | South Plains Oncology ConsortiumNETWORK | 1 | Aug 27, 2020 | clinicaltrials |
| NCT02661815 | A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer | terminated | Phase 1 | 6 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT00407407 | ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma | terminated | Phase 1 | 6 | CelgeneINDUSTRY | 1 | Oct 18, 2019 | clinicaltrials |
| NCT01083537 | Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction | terminated | Phase 1 / Phase 2 | 1 | University Health Network, TorontoOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT00910000 | Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer | terminated | Phase 1 / Phase 2 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00903630 | Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00287859 | Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | terminated | Phase 1 | 5 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00637390 | A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer. | terminated | Phase 1 | 3 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 2, 2016 | clinicaltrials |
| NCT01202890 | Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer | terminated | Phase 1 | 1 | New Mexico Cancer Research AllianceOTHER | 1 | Jan 8, 2014 | clinicaltrials |
| NCT00085384 | PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer | terminated | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2012 | clinicaltrials |
Data updated 4 days agoSource updated Sep 22, 2026source: clinicaltrials